A fully magnetically LVAD substantially reduced ischemic and bleeding events compared with conventional centrifugal-flow devices, according to findings published in the Journal of the American College of Cardiology (JACC).

The study evaluated 4,320 patients from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS), including 2,232 with magnetically levitated pumps and 2,088 with conventional centrifugal-flow devices. From 2 weeks to 2 years post-implantation, the magnetically levitated group demonstrated significantly fewer ischemic hemocompatibility-related events (2.9% vs 15.3% per 100 patient-years; P < 0.001) and fewer major bleeding events (11.8% vs 18%; P < 0.001).

Although bleeding remained the most common complication, both ischemic and bleeding events were independently linked to higher all-cause mortality. The findings suggest that magnetically levitated technology has redefined the safety profile of LVAD therapy and emphasize the need for precision-based antithrombotic management to maximize long-term survival.